Allos' Folotyn and Gloucster's Istodax: Exceptions That Prove The Rule?
This article was originally published in The Pink Sheet Daily
Executive Summary
ODAC continues to emphasize the importance of randomized controlled trials while supporting approval for two t-cell lymphoma drugs that conducted only singe-arm studies.
You may also be interested in...
Slower Deal-Making Year In Oncology Leaves Numerous Appealing Targets
In terms of oncology alliances, 2009 is shaping up as slower than the previous three years, but the number of significantly priced deals has not decreased greatly
Slower Deal-Making Year In Oncology Leaves Numerous Appealing Targets
In terms of oncology alliances, 2009 is shaping up as slower than the previous three years, but the number of significantly priced deals has not decreased greatly
Gloucester's Istodax Gains FDA Approval Ahead Of New Regulatory Requirements
With FDA's approval a week ahead of the PDUFA date, Gloucester Pharmaceuticals will bring its first product to market, the second HDAC inhibitor approved in cancer.